The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical trial

Publisher: John Wiley & Sons Inc

E-ISSN: 1365-2249|191|2|229-239

ISSN: 0009-9104

Source: CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol.191, Iss.2, 2018-02, pp. : 229-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content